Most Read Articles
Elaine Soliven, 5 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Serlopitant safe, effective for pruritus in mild-to-moderate psoriasis

29 May 2020

Serlopitant appears to reduce pruritus in patients with mild-to-moderate psoriasis, a new trial has shown.

The researchers randomly assigned 203 patients to receive either 5 mg serlopitant (n=102; mean age, 48.2±15.2 years; 52.9 percent male) or placebo (n=101; mean age, 46.7±12.3 years; 38.6 percent male), given over 8 weeks of treatment. The primary efficacy endpoint was responder rate at week 8, quantified using the worst itch numeric rating scale (WI-NRS).

A third (33.3 percent) of the patients in the serlopitant arm achieved a 4-point improvement in the WI-NRS after 8 weeks of treatment. In comparison, the rate of similar improvement in the placebo arm was 21.1 percent (p=0.028).

Serlopitant also fulfilled the key secondary endpoint of a 4-point WI-NRS improvement over 4 weeks. This was reported in 20.8 percent of the serlopitant group, as opposed to only 11.5 percent of the placebo comparators (p=0.039).

The key absolute change values for WI-NRS were also greater for the serlopitant arm when measured by day 3 (–0.744±1.464 vs –0.455±1.318) and day 7 (–1.338±2.025 vs –0.780±1.618). The principal findings were generally maintained across subgroups of age, sex, weight, body surface area, and baseline WI-NRS score.

These efficacy advantages did not come with excess safety concerns. The incidence of treatment-emergent adverse events (TEAEs), for example, was comparable between the serlopitant and placebo groups (37.3 percent vs 35.0 percent). Most of the cases were of mild or moderate severity, and no serious TEAEs were reported in the serlopitant arm.

Editor's Recommendations
Most Read Articles
Elaine Soliven, 5 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.